Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:32:46 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:SNDX from 2023-04-20 to 2024-04-19 - 45 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-10 16:05U:SNDXNews ReleaseSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
2024-04-08 07:00U:SNDXNews ReleaseSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
2024-04-05 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-03-28 07:00U:SNDXNews ReleaseSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
2024-03-26 16:05U:SNDXNews ReleaseSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
2024-03-18 07:00U:SNDXNews ReleaseSyndax Announces Appointment of Steven Closter as Chief Commercial Officer
2024-03-01 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-27 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
2024-02-26 07:00U:SNDXNews ReleaseSyndax Announces Participation at Two Upcoming Investor Conferences
2024-02-20 16:05U:SNDXNews ReleaseSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
2024-02-02 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-01 16:10U:SNDXNews ReleaseSyndax Announces Participation at Two Upcoming Investor Conferences
2024-01-05 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-01-02 16:05U:SNDXNews ReleaseSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 07:00U:SNDXNews ReleaseSyndax Highlights Recent Updates and Anticipated 2024 Milestones
2023-12-19 16:16U:SNDXNews ReleaseSyndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
2023-12-14 23:07U:SNDXNews ReleaseSyndax Announces Pricing of $200 Million Public Offering of Common Stock
2023-12-14 16:00U:SNDXNews ReleaseSyndax Announces Proposed $150 Million Public Offering of Common Stock
2023-12-12 12:00U:SNDXNews ReleaseSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
2023-12-11 07:30U:SNDXNews ReleaseSyndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
2023-12-04 07:00U:SNDXNews ReleaseSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
2023-12-01 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-11-21 09:00U:SNDXNews ReleaseSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
2023-11-07 07:00U:SNDXNews ReleaseSyndax Announces Participation at Stifel Healthcare Conference
2023-11-03 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-11-02 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
2023-11-02 09:00U:SNDXNews ReleaseSyndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
2023-11-02 09:00U:SNDXNews ReleaseSyndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
2023-10-26 07:00U:SNDXNews ReleaseSyndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023
2023-10-24 07:00U:SNDXNews ReleaseSyndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
2023-10-06 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-10-02 07:00U:SNDXNews ReleaseSyndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
2023-09-29 16:05U:SNDXNews ReleaseSyndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
2023-09-01 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-08-31 16:05U:SNDXNews ReleaseSyndax Announces Participation at the Citi 18th Annual BioPharma Conference
2023-08-04 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-08-03 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
2023-07-25 07:00U:SNDXNews ReleaseSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023
2023-07-24 07:00U:SNDXNews ReleaseSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
2023-07-07 16:13U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-06-02 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-24 07:00U:SNDXNews ReleaseSyndax Announces Participation at Two Upcoming Investor Conferences
2023-05-08 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
2023-05-04 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-01 07:00U:SNDXNews ReleaseSyndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023